Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment

Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, Chikashi Ishioka

研究成果: Article査読

抄録

Anti-EGFR antibodies were designed to inhibit the receptor tyrosine kinase activity of EGFR by directly binding to the extracellular domain. Anti-EGFR antibodies have been approved or will be approved for use in Japan, the USA or Europe. Recently, many studies have investigated molecular markers can predict the response to anti-EGFR antibodies so as to discriminate responders and non-responders. Activating KRAS mutation has been shown to be a potent predictive marker of resistance to anti-EGFR antibodies. Moreover, BRAF mutations, PIK3CA mutations or loss of PTEN have also been shown to be other molecular markers to predict resistance to anti-EGFR antibodies. Further studies must integrate these markers into clinical decisions to use or not use anti-EGFR antibodies.

本文言語English
ページ(範囲)1063-1066
ページ数4
ジャーナルJapanese Journal of Cancer and Chemotherapy
36
7
出版ステータスPublished - 2009 7

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント 「Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル